Leerink keeps Boston Scientific at Outperform, cuts price target to $50
Leerink Partners kept its Outperform rating on Boston Scientific shares but lowered the price target from $55 to $50. TradingView reported the change.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Leerink Partners kept its Outperform rating on Boston Scientific but reduced its price target from $55 to $50, a 9.1% cut. Based on the October 28 close of $42.43, the new target implies a 17.8% upside. The information comes from TradingView.
Among the five most recent analyst notes over the past 30 days, price targets range from $45 to $57. UBS holds a Buy rating with a $57 target, Wells Fargo has Equal-Weight at $45, and Baird has Outperform at $51. The rating data is provided by Benzinga.
why it matters
For investors this is a routine event: one adjustment reflects a single analyst's view rather than a decision by the company itself. Comparing it with other targets shows that opinions on the stock vary considerably.
tags
instruments
sources
- Leerink Partners maintains Boston Scientific at Outperform, lowers price target to $50 from $55 — TradingView, 29 October 2026 at 18:54 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗